From the record

Amgen and AstraZeneca reported trial results showing their combination of tarlatamab and durvalumab improved survival in patients with extensive-stage small-cell lung cancer.

Items older than 7 days — their verdicts, sources and coverage history — are part of the Azimuth Daily record and available to signed-in readers.